Using a molecule designed to overcome a roadblock formed by a common type of genetic flaw, researchers at the University of Wisconsin-Madison have made progress towards novel molecular treatments for Friedreich’s ataxia—a rare but fatal disorder—in the laboratory dish and in animals.